Research programme: neglected parasitic disease therapeutics - MMV/DNDi/Evotec

Drug Profile

Research programme: neglected parasitic disease therapeutics - MMV/DNDi/Evotec

Alternative Names: Chaga's disease therapeutics - DNDi/MMV; Leishmaniasis therapeutics - DNDi/MMV; Therapeutics for neglected tropical diseases (NTDs) - Drugs for Neglected Diseases initiative/Medicines for Malaria Venture; Trypanosomiasis therapeutics - DNDi/MMV

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; Medicines for Malaria Venture
  • Developer Drugs for Neglected Diseases Initiative Foundation; Evotec AG; Medicines for Malaria Venture
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Falciparum malaria
  • No development reported Chagas disease; Filariasis; Leishmaniasis; Trypanosomiasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Filariasis in Belgium
  • 16 Jul 2016 No recent reports of development identified for research development in Filariasis in Switzerland
  • 16 Jul 2016 No recent reports of development identified for research development in Trypanosomiasis in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top